| Name | Transcriptional coactivator YAP1 | ||
| UniProt ID | YAP1_HUMAN | ||
| Gene Name | YAP1 | ||
| Gene ID | 10413 | ||
| Synonyms |
YAP1, COB1, YAP, YAP-1, YAP2, YAP65, YKI
|
||
| Sequence |
MDPGQQPPPQPAPQGQGQPPSQPPQGQGPPSGPGQPAPAATQAAPQAPPAGHQIVHVRGD
SETDLEALFNAVMNPKTANVPQTVPMRLRKLPDSFFKPPEPKSHSRQASTDAGTAGALTP QHVRAHSSPASLQLGAVSPGTLTPTGVVSGPAATPTAQHLRQSSFEIPDDVPLPAGWEMA KTSSGQRYFLNHIDQTTTWQDPRKAMLSQMNVTAPTSPPVQQNMMNSASGPLPDGWEQAM TQDGEIYYINHKNKTTSWLDPRLDPRFAMNQRISQSAPVKQPPPLAPQSPQGGVMGGSNS NQQQQMRLQQLQMEKERLRLKQQELLRQAMRNINPSTANSPKCQELALRSQLPTLEQDGG TQNPVSSPGMSQELRTMTTNSSDPFLNSGTYHSRDESTDSGLSMSSYSVPRTPDDFLNSV DEMDTGDTINQSTLPSQQNRFPDYLEAIPGTNVDLGTLEGDGMNIEGEELMPSLQEALSS DILNDMESVLAATKLDKESFLTWL |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 2.A.5.1.1 | ||
| KEGG ID | hsa10413 | ||
| TTD ID | T94048 | ||
| Pfam | PF00397; PF03621; PF15238 | ||
| Pair Name | Platycodin D, Oxaliplatin | |||
| Phytochemical | Platycodin D | |||
| Drug | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Regulate Info | Down-regulation | Transcriptional coactivator YAP1 | Phosphorylation | |
| Result | Our results showed that PD is suitable as a promising agent for overcoming oxaliplatin-resistant colorectal cancer. | |||
| Pair Name | Pterostilbene, Osimertinib | |||
| Phytochemical | Pterostilbene | |||
| Drug | Osimertinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Regulate Info | Down-regulation | Transcriptional coactivator YAP1 | Phosphorylation | |
| Result | The results of this study indicate that pterostilbene may be used to abrogate the activated resistance pathways of single osimertinib treatment in EGFR-mutation positive NSCLC. Future studies should focus on in vivo translation and confirmation of these results. | |||
| Pair Name | Ursolic acid, Doxorubicin | |||
| Phytochemical | Ursolic acid | |||
| Drug | Doxorubicin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Regulate Info | Up-regulation | Transcriptional coactivator YAP1 | Phosphorylation | |
| Result | UA may be a novel anticancer strategy and could be considered for investigation as a complementary chemotherapy agent in the future. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Platycodin D confers oxaliplatin Resistance in Colorectal Cancer by activating the LATS2/YAP1 axis of the hippo signaling pathway. J Cancer. 2023 Jan 22;14(3):393-402. doi: 10.7150/jca.77322. | Click |
| 2 | Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). Int J Biol Sci. 2019 Sep 7;15(12):2607-2614. doi: 10.7150/ijbs.32889. | Click |
| 3 | Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway. Mol Med Rep. 2023 Jan;27(1):11. doi: 10.3892/mmr.2022.12898. | Click |
